ANAPTYSBIO INC (ANAB)
US0327241065 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to ANAB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 46.13. This target is 140.49% above the current price.
ANAB was analyzed by 15 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ANAB.
In the previous month the buy percentage consensus was at a similar level.
ANAB was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-16 | Leerink Partners | Initiate | Outperform |
| 2024-04-11 | Wells Fargo | Initiate | Overweight |
| 2024-04-01 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-03-12 | Wedbush | Upgrade | Neutral -> Outperform |
| 2024-02-26 | BTIG | Initiate | Buy |
| 2024-02-21 | Stifel | Initiate | Buy |
| 2024-02-16 | Piper Sandler | Initiate | Overweight |
| 2023-11-29 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-11-03 | Wedbush | Maintains | Neutral -> Neutral |
| 2023-11-02 | UBS | Maintains | Neutral -> Neutral |
| 2023-08-08 | Wedbush | Maintains | Neutral -> Neutral |
| 2023-05-22 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2023-05-12 | Guggenheim | Maintains | Buy -> Buy |
| 2023-05-12 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-04-12 | JP Morgan | Maintains | Underweight |
| 2023-01-06 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2022-11-18 | JP Morgan | Maintains | Underweight |
| 2022-11-09 | Raymond James | Maintains | Outperform |
| 2022-11-01 | Guggenheim | Upgrade | Neutral -> Buy |
| 2022-09-13 | Truist Securities | Downgrade | Buy -> Hold |
| 2022-09-01 | Raymond James | Initiate | Outperform |
| 2022-03-08 | HC Wainwright & Co. | Maintains | Buy |
| 2021-06-22 | HC Wainwright & Co. | Initiate | Buy |
| 2021-05-21 | UBS | Initiate | Neutral |
| 2021-03-16 | Truist Securities | Upgrade | Hold -> Buy |
| 2021-03-09 | Wedbush | Downgrade | Outperform -> Neutral |
| 2021-02-11 | JP Morgan | Upgrade | Underweight -> Overweight |